BLDpharm

SAFETY DATA SHEET

SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identification

Product Description: Cat No. : UFI: CAS-No Molecular Formula	N-(3-(5-(2-Aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6- difluorobenzenesulfonamide BD289532 N/A 1195765-45-7 C23H20F3N5O2S2
1.2. Relevant identified uses of the	substance or mixture and uses advised against
Identified uses Uses advised against	For laboratory research purposes.Not for drug or household use. No Information available
1.3. Details of the supplier of the sa	ately data sheet
company:	BLD Pharmatech GmbH
address:	Senefelder-Ring 27, 21465 Reinbek, Germany.
Telephone:	+49 (0)4055 822 764 0
<u>1.4. Emergency telephone</u> Emergency Phone:	1-352-323-3500
Linergency Flione.	0800 1812924

SECTION 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

CLP Classification - Regulation (EC) No 1272/2008

<u>Physical hazards</u> Based on available data, the classification criteria are not met

Health hazards

Acute toxicity, oral Skin corrosion/irritation Serious eye damage/eye irritation Specific target organ toxicity, single exposure;Respiratory system

Environmental hazards

Based on available data, the classification criteria are not met

2.2. Label elements



Signal Word

Warning

Hazard Statements

- H302 Harmful if swallowed
- H315 Causes skin irritation
- H319 Causes serious eye irritation
- H335 May cause respiratory irritation

Precautionary Statements

P261 - Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

2.3. Results of PBT and vPvB assessment

Category 4 (H302) Category 2 (H315) Category 2A (H319) Category 3 (H335)



PBT: vPvB: Not applicable

Not applicable

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1. Substances

Component	CAS-No	Molecular Weight	CLP Classification - Regulation (EC) No1272/2008	Concentration
N-(3-(5-(2-Aminopyrimidin-4-yl)-2- (tert-butyl)thiazol-4-yl)-2- fluorophenyl)-2,6- difluorobenzenesulfonamide	1195765- 45-7	519.5624	Acute toxicity, oral 4 (H302) Skin corrosion/irritation 2 (H315) Serious eye damage/eye irritation 2A (H319) Specific target organ toxicity, single exposure;Respiratory system 3 (H335)	<=100%

SECTION 4: FIRST AID MEASURES

4.1. Description of first aid measures

General Advice	If symptoms persist, call a physician.	
Eye Contact	Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. Get medical attention.	
Skin Contact	Wash off immediately with plenty of water for at least 15 minutes. If skin irritation persists, call a physician.	
Ingestion	Clean mouth with water and drink afterwards plenty of water. Get medical attention if symptoms occur.	
Inhalation	Move to fresh air. If not breathing, give artificial respiration. Get medical attention if symptoms occur.	
Self-Protection of the First Aider	Ensure that medical personnel are aware of the material(s) involved, take precautions to protect themselves and prevent spread of contamination.	
4.2. Most important symptoms and effects, both acute and delayed		
	None reasonably foreseeable.	

4.3. Indication of any immediate medical attention and special treatment needed

Notes to Physician

Treat symptomatically.

SECTION 5: FIREFIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

Extinguishing media which must not be used for safety reasons No information available.

5.2. Special hazards arising from the substance or mixture

Thermal decomposition can lead to release of irritating gases and vapors.

Hazardous Combustion Products No data available

5.3. Advice for firefighters

As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective gear.

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Ensure adequate ventilation. Use personal protective equipment. Avoid dust formation.

6.2. Environmental precautions

Should not be released into the environment.

6.3. Methods and material for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable container for disposal. Keep in suitable, closed containers for disposal.



BLD Pharmatech

6.4. Reference to other sections

Refer to protective measures listed in Sections 8 and 13.

SECTION 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Wear personal protective equipment. Ensure adequate ventilation. Do not get in eyes, on skin, or on clothing. Avoid ingestion and inhalation. Avoid dust formation.

Hygiene Measures

Handle in accordance with good industrial hygiene and safety practice. Keep away from food, drink and animal feeding stuffs. Do not eat, drink or smoke when using this product. Remove and wash contaminated clothing before re-use. Wash hands before breaks and at the end of workday.

7.2. Conditions for safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated area. Containers which are opened must be carefully resealed and kept upright to prevent leakage.Keep in dark place, lnert atmosphere, Room temperature

7.3. Specific end use(s)

Use in laboratories

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure limits

This product, as supplied, does not contain any hazardous materials with occupational exposure limits established by the region specific regulatory bodies

Biological limit values

This product, as supplied, does not contain any hazardous materials with biological limits established by the region specific regulatory bodies

Monitoring methods

BS EN 14042:2003 Title Identifier: Workplace atmospheres. Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents.

MDHS14/3 General methods for sampling and gravimetric analysis of respirable and inhalable dust

Derived No Effect Level (DNEL) No information available.

Route of exposure	Acute effects (local)	Acute effects (systemic)	Chronic effects (local)	Chronic effects (systemic)
Oral				
Dermal				
Inhalation				

Predicted No Effect Concentration (PNEC) No information available.

8.2. Exposure controls

Engineering Measures

Ensure adequate ventilation, especially in confined areas. Ensure that eyewash stations and safety showers are close to the workstation location. Wherever possible, engineering control measures such as the isolation or enclosure of the process, the introduction of process or equipment changes to minimise release or contact, and the use of properly designed ventilation systems, should be adopted to control hazardous materials at source.

Personal protective equipment

Eye Protection	Goggles (European standard - EN 166)			
Hand Protection	Protective glov	es		
Glove material Nitrile rubber Neoprene Natural rubber PVC	Breakthrough time See manufacturers recommendations	Glove thickness -	EU standard EN 374	Glove comments (minimum requirement)

Skin and body protection

Long sleeved clothing

Inspect gloves before use.

Please observe the instructions regarding permeability and breakthrough time which are provided by the supplier of the gloves. (Refer to manufacturer/supplier for information)

Ensure gloves are suitable for the task: Chemical compatability, Dexterity, Operational conditions, User susceptibility, e.g. sensitisation effects, also take into consideration the specific local conditions under which the product is used, such as the danger of cuts, abrasion.



BLD Pharmatech

Remove gloves with care avoiding skin contamination.

Respiratory Protection	No protective equipment is needed under normal use conditions.
Large scale/emergency use	Use a NIOSH/MSHA or European Standard EN 136 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced
Small scale/Laboratory use	Maintain adequate ventilation
Environmental exposure controls	No information available.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state Colour	White to Yellow Solid
Odour	No information available
Odour Threshold	No data available
рН	No information available
Melting Point/Range	No data available
Softening Point	No data available
Boiling Point/Range	No data available
Flash Point	No data available
Evaporation Rate	Not applicable
Flammability (solid,gas)	No information available
Explosion Limits	No data available
Vapor Pressure	No data available
Vapor Density	Not applicable
Oxidizing properties	No data available
Specific Gravity / Density	No data available
Bulk Density	No data available
Water Solubility	No information available
Solubility in other solvents	No information available
Partition Coefficient (n-octanol/water)	No data available
Autoignition Temperature	No data available
Decomposition Temperature	No data available
Viscosity	Not applicable
Explosive Properties	No information available
Particle characteristics	No data

9.2. Other information

Molecular Formula Molecular Weight C23H20F3N5O2S2 519.5624

SECTION 10: STABILITY AND REACTIVITY

10.1. Reactivity

None known, based on information available

10.2. Chemical stability

Stable under normal conditions.

10.3. Possibility of hazardous reactions

Hazardous Polymerization	No information available.
Hazardous Reactions	None under normal processing.

10.4. Conditions to avoid

Not data available

10.5. Incompatible materials

Not data available

10.6. Hazardous decomposition products

Carbon monoxide , carbon dioxide , hydrogen fluoride , nitrogen oxides , oxides of sulfur



11.1. Information on toxicological effects

(a) acute toxicity;	No data available
(b) skin corrosion/irritation;	No data available
(c) serious eye damage/irritation;	No data available
(d) respiratory or skin sensitization;	
Respiratory	No data available
Skin	No data available
(e) germ cell mutagenicity;	No data available
(f) carcinogenicity;	No data available
(g) reproductive toxicity;	No data available
(h) STOT-single exposure;	No data available
Results / Target organs	No data available
(i) STOT-repeated exposure;	No data available
Target Organs	None known
(j) aspiration hazard;	No data available
Other Adverse Effects	No data available
Symptoms / effects, both acute and delayed	No data available

11.2. Additional Information

To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

SECTION 12: ECOLOGICAL INFORMATION

12.1. Toxicity	
Ecotoxicity effects	No information available
12.2. Persistence and degradability	No information available
12.3. Bioaccumulative potential	No information available
12.4. Mobility in soil	No information available
<u>12.5. Results of PBT and vPvB</u> assessment	No data available for assessment.
12.6. Endocrine disrupting properties	No data available
12.7. Other adverse effects	
Persistent Organic Pollutant	No data available
Ozone Depletion Potential	No data available

SECTION 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods	
Waste from Residues / Unused Products	Waste is classified as hazardous. Dispose of in accordance with the European Directives on waste and hazardous waste. Dispose of in accordance with local regulations.
Contaminated Packaging	Dispose of this container to hazardous or special waste collection point.
European Waste Catalogue (EWC)	According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.
Other Information	Waste codes should be assigned by the user based on the application for which the product was used. Do not empty into drains.

SECTION 14: TRANSPORT INFORMATION

<u>14.1. UN number</u>		
ADR/RID: -	IMDG: -	IATA: -
14.2. UN proper shipping name ADR/RID: Not dangerous goods	IMDG: Not dangerous goods	IATA: Not dangerous goods
14.3. Transport hazard class(es)		
ADR/RID: -	IMDG: -	IATA: -



BLD Pharmatech

14.4. Packaging group

ADR/RID: -	IMDG: -	IATA: -
14.5. Environmental hazards		
ADR/RID: -	IMDG: -	IATA: -

14.6. Special precautions for user

No special precautions required

14.7. Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code

Not applicable, packaged goods

14.8. Further information

No data available

SECTION 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.

15.2. Safety Assessment

No Chemical Safety Assessment

SECTION 16: OTHER INFORMATION

16.1. The reference company name of written contents

Company:	BLD Pharmatech GmbH
Address:	Senefelder-Ring 27, 21465 Reinbek, Germany.
Telephone:	+49 (0)4055 822 764 0

This SDS was prepared sincerely on the basis of the information we could obtained, however, any warranty shall not be given regarding the data contained and the assessment of hazards and toxicity. Prior to use, please investigate not only the hazards and toxicity information but also the laws and regulations of the organization, area and country where the products are to be used, which shall be given the first priority. products are supposed to be used promptly after purchase in consideration of safety. Some new information or amendments may be added afterwards. If the products are to be used far behind the expected time of use or you have any questions, please feel free to contact us. The stated cautions are for normal handling only. In case of special handling, sufficient care should be taken, in addition to the safety measures suitable for the situation. All chemical products should be treated with the recognition of "having unknown hazards and toxicity", which differ greatly depending on the conditions and handling when in use and/or the conditions and duration of storage. The products must be handled only by those who are familiar with specialized knowledge and have experience or under the guidance of those specialists throughout use from opening to storage and disposal. Safe usage conditions shall be set up on each user's own responsibility.

Revision Date 09/12/2024 Print Date 03/11/2025